Dr David Sheridan
Profiles

Dr David Sheridan

Associate Professor & Honorary Consultant in Hepatology

Peninsula Medical School (Faculty of Health)

Biography

Biography

Dr Sheridan is Associate Professor in Hepatology at Peninsula Medical School and Honorary Consultant Hepatologist at the South West Liver Unit, Derriford Hospital. He was Clinical Service Line Director for the South West Liver Unit (2019-2023), until taking up current tenure as Clinical Director of the Medicine Care Group at University Hospitals Plymouth NHS Trust. Research interests are in chronic hepatitis C virus and metabolic-dysfunction associated steatotic liver disease (MASLD).

Qualifications

BSc Immunology & Cell Pathology, University College London 1997
MB BS Royal Free & University College London Medical School 2000 (with distinction)
MRCP(UK) 2003
PhD Newcatle University 2010FRCP 2020
Previous posts:
PRHO Whittington Hospital, London 2000–2001
SHO University Hospitals Leicester medical rotation 2001–2004
Specialist Registrar Gastroenterology and Hepatology, Northern Deanery 2004–2014
MRC Clinical Research Fellow, Newcastle University 2007–2010
NIHR Academic Clinical Lecturer Newcastle University 2011–2014
Sub-specialty NTN in Hepatology and Liver Transplantation, Freeman Hospital, Newcastle upon Tyne 2012–13
Visiting Scholar, Storr liver Unit, Westmead Millenium Institute, University of Sydney 2013–14

Professional membership

GMC 4718282
Royal College of Physicians of London
British Society for the Study of the Liver (BASL)
European Society for the study of the Liver (EASL)

Key publications

Eddowes PJ, Sasso M, Allison M, Tsochatzis E, Anstee QM, Sheridan D, Guha IN, Cobbold JF, Deeks JJ & Paradis V (2019) 'Accuracy of FibroScan Controlled Attenuation Parameter and Liver Stiffness Measurement in Assessing Steatosis and Fibrosis in Patients With Non-alcoholic Fatty Liver Disease' Gastroenterology ,
Macken L, Bremner S, Gage H, Touray M, Williams P, Crook D, Mason L, Lambert D, Evans CJ & Cooper M (2020) 'Randomised clinical trial: palliative long-term abdominal drains vs large-volume paracentesis in refractory ascites due to cirrhosis' Alimentary Pharmacology & Therapeutics 52, (1) 107-122 ,
Younossi ZM, Ratziu V, Loomba R, Rinella M, Anstee QM, Goodman Z, Bedossa P, Geier A, Beckebaum S & Newsome PN (2019) 'Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial' The Lancet ,
Jones D, Boudes PF, Swain MG, Bowlus CL, Galambos MR, Bacon BR, Doerffel Y, Gitlin N, Gordon SC & Odin JA (2017) 'Seladelpar (MBX-8025), a selective PPAR-δ agonist, in patients with primary biliary cholangitis with an inadequate response to ursodeoxycholic acid: a double-blind, randomised, placebo-controlled, phase 2, proof-of-concept study' Lancet Gastroenterology & Hepatology ,
Sheridan DA, Aithal G, Alazawi W, Allison M, Anstee Q, Cobbold J, Khan S, Fowell A, McPherson S & Newsome PN (2017) 'Care standards for non-alcoholic fatty liver disease in the United Kingdom 2016: a cross-sectional survey' Frontline Gastroenterology flgastro-2017-100806-flgastro-2017-100806 ,
View all publications
Teaching

Teaching

Teaching interests

Post Graduate Certificate in Clinical Education, 2015. University of PlymouthAcademic Tutor BMBS years 3 and 4
Research

Research

Research interests

Hepatitis C Virus
Lipid metabolism
Non-alcoholic fatty liver disease
Mitochondrial bioenergetics
Clinical Trials

Research groups

Publications

Publications

Key publications

Eddowes PJ, Sasso M, Allison M, Tsochatzis E, Anstee QM, Sheridan D, Guha IN, Cobbold JF, Deeks JJ & Paradis V (2019) 'Accuracy of FibroScan Controlled Attenuation Parameter and Liver Stiffness Measurement in Assessing Steatosis and Fibrosis in Patients With Non-alcoholic Fatty Liver Disease' Gastroenterology ,
Macken L, Bremner S, Gage H, Touray M, Williams P, Crook D, Mason L, Lambert D, Evans CJ & Cooper M (2020) 'Randomised clinical trial: palliative long-term abdominal drains vs large-volume paracentesis in refractory ascites due to cirrhosis' Alimentary Pharmacology & Therapeutics 52, (1) 107-122 ,
Younossi ZM, Ratziu V, Loomba R, Rinella M, Anstee QM, Goodman Z, Bedossa P, Geier A, Beckebaum S & Newsome PN (2019) 'Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial' The Lancet ,
Jones D, Boudes PF, Swain MG, Bowlus CL, Galambos MR, Bacon BR, Doerffel Y, Gitlin N, Gordon SC & Odin JA (2017) 'Seladelpar (MBX-8025), a selective PPAR-δ agonist, in patients with primary biliary cholangitis with an inadequate response to ursodeoxycholic acid: a double-blind, randomised, placebo-controlled, phase 2, proof-of-concept study' Lancet Gastroenterology & Hepatology ,
Sheridan DA, Aithal G, Alazawi W, Allison M, Anstee Q, Cobbold J, Khan S, Fowell A, McPherson S & Newsome PN (2017) 'Care standards for non-alcoholic fatty liver disease in the United Kingdom 2016: a cross-sectional survey' Frontline Gastroenterology flgastro-2017-100806-flgastro-2017-100806 ,

Key publications are highlighted

Journals
Articles
Miller H, Harman D, Aithal GP, Manousou P, Cobbold JF, Parker R, Sheridan D, Newsome PN, Karpe F & Neville M (2024) 'Translating the potential of the urine steroid metabolome to stage NAFLD (TrUSt-NAFLD): study protocol for a multicentre, prospective validation study' BMJ Open 14, (1) e074918-e074918 ,
Mayo MJ, Vierling JM, Bowlus CL, Levy C, Hirschfield GM, Neff GW, Galambos MR, Gordon SC, Borg BB & Harrison SA (2023) 'Featured Cover' Alimentary Pharmacology & Therapeutics 59, (2) ,
Colosimo S, Miller H, Koutoukidis D, Marjot T, Tan G, Harman D, Aithal G, Manousou P, Forlano R & Parker R (2023) 'The role of glycated haemoglobin in predicting disease severity in non-alcoholic fatty liver disease' Endocrine Abstracts ,
Mayo MJ, Vierling JM, Bowlus CL, Levy C, Hirschfield GM, Neff GW, Galambos MR, Gordon SC, Borg BB & Harrison SA (2023) 'Open‐label, clinical trial extension: Two‐year safety and efficacy results of seladelpar in patients with primary biliary cholangitis' Alimentary Pharmacology & Therapeutics ,
Li W, Sheridan D, McPherson S, Alazawi W, Abeysekera K, Marjot T, Brennan P, Mahgoub S, Cacciottolo T & Hydes T (2023) 'National study of NAFLD management identifies variation in delivery of care in the UK between 2019 to 2022' JHEP Reports 5, (12) ,
Boursier J, Roux M, Costentin C, Chaigneau J, Fournier-Poizat C, Trylesinski A, Canivet CM, Michalak S, Le Bail B & Paradis V (2023) 'Practical diagnosis of cirrhosis in non-alcoholic fatty liver disease using currently available non-invasive fibrosis tests' Nature Communications 14, (1) ,
Miller H, Colosimo S, Li W, Cobbold J, Alazawi W, Harman D, Aithal G, Manousou P, Parker R & Newsome PN (2023) 'Developing a risk stratification tool for advanced NAFLD fibrosis using routinely measured clinical variables in a diabetes clinic annual review' Journal of Hepatology 78, S708-S708 ,
Sheridan DA, Shawa IT, Thomas EL, Felmlee DJ, Bridge SH, Neely D, Cobbold JF, Holmes E, Bassendine MF & Taylor-Robinson SD (2022) 'Infection with the hepatitis C virus causes viral genotype-specific differences in cholesterol metabolism and hepatic steatosis' Scientific Reports 12, (1) ,
Bowlus CL, Galambos MR, Aspinall RJ, Hirschfield GM, Jones DEJ, Dörffel Y, Gordon SC, Harrison SA, Kremer AE & Mayo MJ (2022) 'A phase II, randomized, open-label, 52-week study of seladelpar in patients with primary biliary cholangitis' Journal of Hepatology ,
Dhanda AD, Felmlee D, Boeira P, Moodley P, Tan H, Scalioni LDP, Lilly K, Sheridan DA & Cramp ME (2022) 'Patients with moderate to severe COVID-19 have an impaired cytokine response with an exhausted and senescent immune phenotype' Immunobiology 227, (2) ,
Petroff D, Blank V, Newsome PN, Shalimar, Voican CS, Thiele M, de Lédinghen V, Baumeler S, Chan WK & Perlemuter G (2021) 'Assessment of hepatic steatosis by controlled attenuation parameter using the M and XL probes: an individual patient data meta-analysis' The Lancet Gastroenterology & Hepatology 6, (3) 185-198 ,
Ankcorn M, Said B, Morgan D, Elsharkawy AM, Maggs J, Ryder S, Valliani T, Gordon F, Abeysekera K & Suri D (2020) 'Persistent Hepatitis E virus infection across England and Wales 2009‐2017: Demography, virology and outcomes' Journal of Viral Hepatitis 28, (2) 420-430 ,
Macken L, Bremner S, Sheridan D & Verma S (2020) 'Letter: long-term abdominal drains in refractory ascites-evolving concept of palliative care in decompensated cirrhosis. Authors' reply' ALIMENTARY PHARMACOLOGY & THERAPEUTICS 52, (7) 1268-1269 ,
Macken L, Bremner S, Sheridan D & Verma S (2020) 'Editorial: palliative long‐term abdominal drains in refractory ascites—a step in the right direction, but not the complete solution. Authors' reply' Alimentary Pharmacology & Therapeutics 52, (4) 723-724 ,
Macken L, Bremner S, Gage H, Touray M, Williams P, Crook D, Mason L, Lambert D, Evans CJ & Cooper M (2020) 'Randomised clinical trial: palliative long-term abdominal drains vs large-volume paracentesis in refractory ascites due to cirrhosis' Alimentary Pharmacology & Therapeutics 52, (1) 107-122 ,
Newsome PN, Sasso M, Deeks JJ, Paredes A, Boursier J, Chan W-K, Yilmaz Y, Czernichow S, Zheng M-H & Wong VW-S (2020) 'FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study' The Lancet Gastroenterology & Hepatology ,
Younossi ZM, Ratziu V, Loomba R, Rinella M, Anstee QM, Goodman Z, Bedossa P, Geier A, Beckebaum S & Newsome PN (2019) 'Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial' The Lancet ,
Beck A, Hunter H, Jackson S & Sheridan D (2019) 'Acute myeloid leukaemia: an unusual cause of biliary strictures' BMJ Case Reports 12, (3) ,
Sharkawy RE, Bayoumi A, Metwally M, Mangia A, Berg T, Romero-Gomez M, Abate ML, Irving WL, Sheridan D & Dore GJ (2019) 'A variant in the MICA gene is associated with liver fibrosis progression in chronic hepatitis C through TGF-β1 dependent mechanisms' Scientific Reports 9, (1) 1439-1439 ,
Eddowes PJ, Sasso M, Allison M, Tsochatzis E, Anstee QM, Sheridan D, Guha IN, Cobbold JF, Deeks JJ & Paradis V (2019) 'Accuracy of FibroScan Controlled Attenuation Parameter and Liver Stiffness Measurement in Assessing Steatosis and Fibrosis in Patients With Non-alcoholic Fatty Liver Disease' Gastroenterology ,
John M, Metwally M, Mangia A, Romero-Gomez M, Berg T, Sheridan D, George J & Eslam M (2017) 'TLL1 rs17047200 Increases the Risk of Fibrosis Progression in Caucasian Patients With Chronic Hepatitis C' Gastroenterology 153, (5) 1448-1449 ,
Jones D, Boudes PF, Swain MG, Bowlus CL, Galambos MR, Bacon BR, Doerffel Y, Gitlin N, Gordon SC & Odin JA (2017) 'Seladelpar (MBX-8025), a selective PPAR-δ agonist, in patients with primary biliary cholangitis with an inadequate response to ursodeoxycholic acid: a double-blind, randomised, placebo-controlled, phase 2, proof-of-concept study' Lancet Gastroenterology & Hepatology ,
Shawa IT, Sheridan DA, Felmlee DJ & Cramp ME (2017) 'Lipid interactions influence hepatitis C virus susceptibility and resistance to infection' Clinical Liver Disease 10, (1) 17-20 ,
Shawa IT, Felmlee DJ, Hegazy D, Sheridan DA & Cramp ME (2017) 'Exploration of potential mechanisms of HCV resistance in exposed uninfected intravenous drug users' Journal of Viral Hepatitis ,
Sheridan DA, Aithal G, Alazawi W, Allison M, Anstee Q, Cobbold J, Khan S, Fowell A, McPherson S & Newsome PN (2017) 'Care standards for non-alcoholic fatty liver disease in the United Kingdom 2016: a cross-sectional survey' Frontline Gastroenterology flgastro-2017-100806-flgastro-2017-100806 ,
Eslam M, McLeod D, Kelaeng KS, Mangia A, Berg T, Thabet K, Irving WL, Dore GJ, Sheridan D & Grønbæk H (2017) 'IFN-λ3, not IFN-λ4, likely mediates IFNL3-IFNL4 haplotype-dependent hepatic inflammation and fibrosis' Nature Genetics 49, (5) 795-800 ,
Bassendine MF, Nielsen SU, Bridge SH, Felmlee DJ, Sheridan DA, Packard CJ & Neely RD (2016) 'Hepatitis C virus and atherosclerosis: A legacy after virologic cure?' Clinics and Research in Hepatology and Gastroenterology 41, (1) 25-30 ,
Khaled Thabet,, Anastasia Asimakopoulos, Maryam Shojaei, Manuel Romero-Gomez, Alessandra Mangia, William L. Irving, Thomas Berg, Gregory J. Dore, Henning Grønbæk & Sheridan DA (2016) 'MBOAT7 rs641738 increases risk of liver inflammation and transition to fibrosis in chronic hepatitis C' Nature Communications ,
Sheridan DA, Hajarizadeh B, Fenwick FI, Matthews GV, Applegate T, Douglas M, Neely D, Askew B, Dore GJ & Lloyd AR (2016) 'Maximum levels of hepatitis C virus lipoviral particles are associated with early and persistent infection' Liver International ,
Eslam M, Mangia A, Berg T, Chan HLY, Irving WL, Dore GJ, Abate ML, Bugianesi E, Adams LA & Najim MAM (2016) 'Diverse impacts of the rs58542926 E167K variant in TM6SF2 on viral and metabolic liver disease phenotypes' Hepatology 64, (1) 34-46 ,
Eslam M, Hashem AM, Romero-Gomez M, Berg T, Dore GJ, Mangia A, Chan HLY, Irving WL, Sheridan D & Abate ML (2015) 'FibroGENE: A gene-based model for staging liver fibrosis' Journal of Hepatology 64, (2) 390-398 ,
Eslam M, Hashem AM, Leung R, Romero-Gomez M, Berg T, Dore GJ, Chan HLK, Irving WL, Sheridan D & Abate ML (2015) 'Interferon-λ rs12979860 genotype and liver fibrosis in viral and non-viral chronic liver disease' Nature Communications 6, (0) 0-0 ,
Bridge SH, Sheridan DA, Felmlee DJ, Crossey MME, Fenwick FI, Lanyon CV, Dubuc G, Seidah NG, Davignon J & Thomas HC (2014) 'PCSK9, apolipoprotein E and lipoviral particles in chronic hepatitis C genotype 3: Evidence for genotype-specific regulation of lipoprotein metabolism' Journal of Hepatology 62, (4) 763-770 ,
Eslam M, Leung R, Romero-Gomez M, Mangia A, Irving WL, Sheridan D, Spengler U, Mollison L, Cheng W & Bugianesi E (2014) 'IFNL3 polymorphisms predict response to therapy in chronic hepatitis C genotype 2/3 infection' J Hepatol 61, (2) 235-241 ,
Sheridan DA, Bridge SH, Crossey MME, Felmlee DJ, Thomas HC, Neely RDG, Taylor-Robinson SD & Bassendine MF (2014) 'Depressive symptoms in chronic hepatitis C are associated with plasma apolipoprotein E deficiency' Metabolic Brain Disease 29, (3) 625-634 ,
Sheridan DA, Bridge SH, Crossey MME, Felmlee DJ, Fenwick FI, Thomas HC, Neely RDG, Taylor-Robinson SD & Bassendine MF (2013) 'Omega‐3 fatty acids and/or fluvastatin in hepatitis C prior non‐responders to combination antiviral therapy – a pilot randomised clinical trial' Liver International 34, (5) 737-747 ,
Suppiah V, Armstrong NJ, O'Connor KS, Berg T, Weltman M, Abate ML, Spengler U, Bassendine M, Dore GJ & Irving WL (2013) 'CCR5-Δ32 genotype does not improve predictive value of IL28B polymorphisms for treatment response in chronic HCV infection' Genes & Immunity 14, (5) 286-290 ,
Bassendine MF, Sheridan DA, Bridge SH, Felmlee DJ & Neely RDG (2012) 'Lipids and HCV' Seminars in Immunopathology 35, (1) 87-100 ,
Sheridan DA, Neely RDG & Bassendine MF (2012) 'Hepatitis C virus and lipids in the era of direct acting antivirals (DAAs)' Clinics and Research in Hepatology and Gastroenterology 37, (1) 10-16 ,
Sheridan DA, Bridge SH, Felmlee DJ, Crossey MME, Thomas HC, Taylor-Robinson SD, Toms GL, Neely RDG & Bassendine MF (2012) 'Apolipoprotein-E and hepatitis C lipoviral particles in genotype 1 infection: Evidence for an association with interferon sensitivity' Journal of Hepatology 57, (1) 32-38 ,
Suppiah V, Gaudieri S, Armstrong NJ, O'Connor KS, Berg T, Weltman M, Abate ML, Spengler U, Bassendine M & Dore GJ (2011) 'IL28B, HLA-C, and KIR variants additively predict response to therapy in chronic hepatitis C virus infection in a European Cohort: a cross-sectional study' PLoS Med 8, (9) ,
Nkhoma ANS, Sheridan DA, Price DA, Schmid ML, Miller C, Baxter K, Bassendine MF & McPherson S (2011) 'P18 Liver fibrosis assessed by transient elastography predicts response in chronic hepatitis C infected patients treated with PEG-Interferon and Ribavirin' Gut 60, (Suppl 2) A8-A9 ,
Felmlee D, Sheridan D, Bridge S, Packard C, Caslake M, Toms G, Neely D & Bassendine M (2011) 'P44 Use of Intralipid infusion to analyse apolipoprotein B (apoB) and HCV RNA kinetics in chronic infection' Gut 60, (Suppl 2) A21-A21 ,
Bridge S, Sheridan D, Felmlee D, Crossey M, Thomas H, Taylor-Robinson S, Toms G, Neely D & Bassendine M (2011) 'P50 Apolipoprotein E and low-density, apolipoprotein B associated lipoviral particles in chronic hepatitis C infection: evidence for genotype-specific modulation of lipid pathways' Gut 60, (Suppl 2) A24-A24 ,
Bassendine MF, Sheridan DA, Felmlee DJ, Bridge SH, Toms GL & Neely RDG (2011) 'HCV and the hepatic lipid pathway as a potential treatment target' Journal of Hepatology 55, (6) 1428-1440 ,
Sheridan D, Bridge S, Felmlee D, Robinson ST, Thomas H, Toms G, Neely D & Bassendine M (2011) 'The 'interferon paradox' as a predictor of non-response to anti-viral therapy: novel association with apolipoprotein E and hepatitis C virus (HCV) lipoviralparticles (LVP)' Gut 60, (Suppl 1) A55-A56 ,
Sheridan D, Crossey M, Thomas H, Taylor Robinson S, Felmlee D, Bridge S, Toms G, Neely D & Bassendine M (2011) '473 DEPRESSION IN CHRONIC HEPATITIS C IS ASSOCIATED WITH LOW APOLIPOPROTEIN E LEVELS' Journal of Hepatology 54, S193-S193 ,
Smith KR, Suppiah V, O'Connor K, Berg T, Weltman M, Abate M, Spengler U, Bassendine M, Matthews G & Irving WL (2011) 'Identification of improved IL28B SNPs and haplotypes for prediction of drug response in treatment of hepatitis C using massively parallel sequencing in a cross-sectional European cohort' Genome Medicine 3, (8) 57-57 ,
Sheridan DA, Bartlett K, Felmlee DJ, Bridge SH, Toms GL, Dubuc G, Seidah NG, Davignon J, Neely RDG & Bassendine MF (2010) 'Hypocholesterolaemia in chronic Hepatitis C virus (HCV) infection – Reduced production or increased LDL clearance?' Atherosclerosis 213, (1) e4-e4 ,
Bridge SH, Sheridan DA, Felmlee DJ, Toms GL, Neely RDG & Bassendine MF (2010) 'Low density Hepatitis C virus particles (lipoviral particles) associate with insulin resistance in genotype 1 infection' Atherosclerosis 213, (1) e4-e4 ,
Bridge SH, Sheridan DA, Felmlee DJ, Nielsen SU, Thomas HC, Taylor-Robinson SD, Neely RDG, Toms GL & Bassendine MF (2010) 'Insulin resistance and low-density apolipoprotein B-associated lipoviral particles in hepatitis C virus genotype 1 infection' Gut 60, (5) 680-687 ,
McPherson S, Hudson M, Sheridan D, Miller C, Baxter K & Bassendine M (2010) 'P71 Antiviral treatment of recurrent hepatitis C after liver transplantation—the Newcastle experience' Gut 59, (Suppl 2) ,
Felmlee DJ, Sheridan DA, Bridge SH, Nielsen SU, Milne RW, Packard CJ, Caslake MJ, McLauchlan J, Toms GL & Neely RDG (2010) 'Intravascular Transfer Contributes to Postprandial Increase in Numbers of Very-Low-Density Hepatitis C Virus Particles' Gastroenterology 139, (5) 1774-1783.e6 ,
Suppiah V, Moldovan M, Ahlenstiel G, Berg T, Weltman M, Abate ML, Bassendine M, Spengler U, Dore GJ & Powell E (2009) 'IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy' Nat Genet 41, (10) 1100-1104 ,
SHERIDAN DA, PRICE DA, SCHMID ML, TOMS GL, DONALDSON P, NEELY D & BASSENDINE MF (2009) 'Apolipoprotein B‐associated cholesterol is a determinant of treatment outcome in patients with chronic hepatitis C virus infection receiving anti‐viral agents interferon‐alpha and ribavirin' Alimentary Pharmacology & Therapeutics 29, (12) 1282-1290 ,
Letters
Francis J, Sheridan D, Samanta A & Nichol FE (2005) 'Iron deficiency anaemia in chronic inflammatory rheumatic diseases: low mean cell haemoglobin is a better marker than low mean cell volume' Ann Rheum Dis 64, (5) 787-788 ,
Conference Papers
Jothimani D, Govil S, Vij M, Sheridan D, Cramp M & Rela M (2016) 'Predicting Fatty Liver Disease in Healthy Potential Liver Donors' Elsevier BV S479-S479 ,
Sheridan D, Crossey M, Robinson ST, Bridge S, Felmlee D, Thomas H, Toms G, Neely D & Bassendine M (2011) 'Depression in chronic hepatitis C is associated with low apolipoprotein e levels' BMJ A58-A58 ,
Presentations and posters
Macken L, Mason L, Evans C, Steer S, Bremner S, Crook D, Thomson S, Sheridan D, Isaacs P & Wright M Macken L, Mason L, Evans C, Steer S, Bremner S, Crook D, Thomson S, Sheridan D, Isaacs P & Wright M 'PTU-020 REDUCe study: multi-centre feasibility RCT in cirrhosis-related palliative refractory ascites. participant reported outcomes' ,
Macken L, Mason L, Gage H, Jordan J, Touray M, Evans C, Austin M, Parnell N, Cooper M & Steer S Macken L, Mason L, Gage H, Jordan J, Touray M, Evans C, Austin M, Parnell N, Cooper M & Steer S 'PTU-021 Long-term palliative abdominal drains vs large-volume paracentesis in cirrhosis-related refractory ascites: multi-centre feasibility RCT (REDUCe)' ,
Sheridan DA, Gomez Romero M, Bridge S, Crossey M, Shawa IT, Neely D, Felmlee D, Holmes E, Bassendine M & Taylor-Robinson S Sheridan DA, Gomez Romero M, Bridge S, Crossey M, Shawa IT, Neely D, Felmlee D, Holmes E, Bassendine M & Taylor-Robinson S 'P0725 : Lipidomics analysis of fasting serum identifies novel lipid biomarkers specific for HCV genotype 3 and genotype 1 chronic hepatitis C virus infection' ,
Younossi ZM, Stepanova M, Nader F, Loomba R, Anstee QM, Ratziu V, Harrison S, Sanyal AJ, George J & Beckebaum S Younossi ZM, Stepanova M, Nader F, Loomba R, Anstee QM, Ratziu V, Harrison S, Sanyal AJ, George J & Beckebaum S '326 OBESITY-SPECIFIC HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH NON-ALCOHOLIC STEATOHEPATITIS: RESULTS FROM THE REGENERATE STUDY' ,
Moffat A & Sheridan D Moffat A & Sheridan D '8 Thinking ahead clinic' ,
Eddowes P, Allison M, Tsochatzis E, Anstee Q, Sheridan D, Guha IN, Cobbold J, Paradis V, Bedossa P & Newsome P Eddowes P, Allison M, Tsochatzis E, Anstee Q, Sheridan D, Guha IN, Cobbold J, Paradis V, Bedossa P & Newsome P 'Algorithm to identify patients with an activity grade > 2 in type 2 diabetic patients with non-alcoholic fatty liver disease (NAFLD)-development in a large prospective multicenter UK study' ,
Bridge S, Pagano S, Sheridan D, Lodge J, Cramp M, Taylor-Robinson S, Neely D, Vuilleumier N & Bassendine M Bridge S, Pagano S, Sheridan D, Lodge J, Cramp M, Taylor-Robinson S, Neely D, Vuilleumier N & Bassendine M 'Autoantibodies to apolipoprotein A-1 in chronic hepatitis C infection: a role in hepatic fibrosis and cirrhosis?' ,
Newsome PN, Clet M, Czernichow S, Eddowes P, Allison M, Tsochatzis E, Anstee Q, Sheridan D, Guha N & Cobbold J Newsome PN, Clet M, Czernichow S, Eddowes P, Allison M, Tsochatzis E, Anstee Q, Sheridan D, Guha N & Cobbold J 'Expanding the use of the vibration controlled transient elastography in morbid obese patients: validation of a new automated adaptive measurement depths algorithm in a large pooled NAFLD cohort' ,
Boeira P, Affourtit C, Felmlee D & Sheridan D Boeira P, Affourtit C, Felmlee D & Sheridan D 'Investigation of microbiome metabolites and mitochondrial function in non-alcoholic fatty liver disease' ,
Younossi ZM, Stepanova M, Nader F, Loomba R, Anstee Q, Ratziu V, Harrison S, Sanyal A, George J & Beckebaum S Younossi ZM, Stepanova M, Nader F, Loomba R, Anstee Q, Ratziu V, Harrison S, Sanyal A, George J & Beckebaum S 'Obesity-specific health-related quality of life in patients with non-alcoholic steatohepatitis: results from the regenerate study' ,
Eddowes P, Allison M, Tsochatzis E, Anstee Q, Sheridan D, Guha IN, Cobbold J, Paradis V, Bedossa P & Newsome P Eddowes P, Allison M, Tsochatzis E, Anstee Q, Sheridan D, Guha IN, Cobbold J, Paradis V, Bedossa P & Newsome P 'Performance of controlled attenuation parameter (CAP) to assess steatosis in a large prospective multicentre UK study of patients with non-alcoholic fatty liver disease (NAFLD)' ,
Boudes P, Michael G, Bowlus C, Hirschfield G, Jones D, Odin J, Sheridan D, Gitlin N, Harrison S & Hassanein T Boudes P, Michael G, Bowlus C, Hirschfield G, Jones D, Odin J, Sheridan D, Gitlin N, Harrison S & Hassanein T 'Pharmacokinetics and pharmacodynamics of seladelpar, a potent and selective PPAR-delta, in patients with primary biliary cholangitis' ,
Bassendine M, Pagano S, Bridge S, Sheridan D, Shawa I, Cramp M, Taylor-Robinson S, Neely D & Vuilleumier N Bassendine M, Pagano S, Bridge S, Sheridan D, Shawa I, Cramp M, Taylor-Robinson S, Neely D & Vuilleumier N 'SAT-221-Autoantibodies to apolipoprotein A1 (apoA-1): A new prognostic biomarker in HCV infection' ,
Eddowes P, Allison M, Tsochatzis E, Anstee Q, Sheridan D, Guha IN, Cobbold J, Paradis V & Newsome PBP Eddowes P, Allison M, Tsochatzis E, Anstee Q, Sheridan D, Guha IN, Cobbold J, Paradis V & Newsome PBP 'SAT-292-Effectively reducing screen failure rate in non-alcoholic fatty liver disease clinical trial using the FibroScan-based FAST score combining liver stiffness, controlled attenuation parameter and AST' ,
Eddowes P, Allison M, Tsochatzis E, Anstee Q, Sheridan D, Guha IN, Cobbold J, Paradis V & Newsome PBP Eddowes P, Allison M, Tsochatzis E, Anstee Q, Sheridan D, Guha IN, Cobbold J, Paradis V & Newsome PBP 'SAT-293-Combination of FibroScan and FibroMeter (FibroMeter VCTE) improves identification of patients with advanced fibrosis in patients with NAFLD' ,
Shawa I, Bennett K, Sheridan D, Felmlee D, Hegazy D, Ahmed A, Wood C, Jackson S, Fejer G & Cramp M Shawa I, Bennett K, Sheridan D, Felmlee D, Hegazy D, Ahmed A, Wood C, Jackson S, Fejer G & Cramp M 'Upregulated innate immune responses in a hepatitis C virus exposed uninfected cohort' ,
Allison M, Sheridan D & Digpal K Allison M, Sheridan D & Digpal K 'P22 Obeticholic acid improves transaminases in patients with non-alcoholic steatohepatitis: results from the 18-month interim analysis of the REGENERATE study' ,
Macken L, Mason L, bremner S, Gage H, Touray M, Evans C, Cooper M, Timeyin J, Steer S & Lambert D Macken L, Mason L, bremner S, Gage H, Touray M, Evans C, Cooper M, Timeyin J, Steer S & Lambert D 'SAT-076-Long term palliative abdominal drains versus large volume paracentesis in refractory ascites due to cirrhosis: a multi-centre feasibility randomised controlled trial (the REDUCe Study)' ,
Sheridan DA, Felmlee DJ, Bridge SH, Fenwick F, Askew B, Neely D, Crossey MME, Taylor-Robinson SD, Toms GL & Bassendine MF Sheridan DA, Felmlee DJ, Bridge SH, Fenwick F, Askew B, Neely D, Crossey MME, Taylor-Robinson SD, Toms GL & Bassendine MF '493 METABOLIC SYNDROME AND INSULIN RESISTANCE ARE ASSOCIATED WITH MAXIMUM HEPATITIS C LIPOVIRAL PARTICLES IN GENOTYPE 1 INFECTION' ,
Sheridan DA, Bridge SH, Crossey MME, Felmlee DJ, Fenwick F, Thomas HC, Neely D, Taylor-Robinson SD & Bassendine MF Sheridan DA, Bridge SH, Crossey MME, Felmlee DJ, Fenwick F, Thomas HC, Neely D, Taylor-Robinson SD & Bassendine MF '903 OMEGA-3 FATTY ACIDS AND/OR FLUVASTATIN IN HEPATITIS C PRIOR NON-RESPONDERS TO COMBINATION ANTI-VIRAL THERAPY – A PILOT RANDOMISED CLINICAL TRIAL' ,
Sheridan D, Bartlett K, Felmlee D, Bridge SH, Toms GL, Dubuc G, Nabil S, Davignon J, Neely D & Bassendine MF Sheridan D, Bartlett K, Felmlee D, Bridge SH, Toms GL, Dubuc G, Nabil S, Davignon J, Neely D & Bassendine MF '1078 HYPOCHOLESTEROLAEMIA IN CHRONIC HEPATITIS C GENOTYPE 3 INFECTION IS DUE TO BOTH REDUCED CHOLESTEROL PRODUCTION AND INCREASED LDL CLEARANCE' ,
Bridge SH, Sheridan DA, Felmlee DJ, Nielsen SU, Neely RDG, Toms GL & Bassendine MF Bridge SH, Sheridan DA, Felmlee DJ, Nielsen SU, Neely RDG, Toms GL & Bassendine MF '1079 INSULIN RESISTANCE CORRELATES WITH LOW DENSITY HEPATITIS C VIRUS PARTICLES IN GENOTYPE 1 INFECTION' ,
Nielsen S, Sheridan D, Bridge S, Felmlee D, Neely D, Toms G & Bassendine M Nielsen S, Sheridan D, Bridge S, Felmlee D, Neely D, Toms G & Bassendine M '869 CHARACTERIZATION OF HEPATITIS C VIRUS PARTICLES IN HUMAN PLASMA: ASSOCIATION WITH IMMUNOGLOBULINS G1, G3 & M AND APOLIPOPROTEINS A-I, A-II, B, C-I AND E' ,
Personal

Personal

Other academic activities

Editorial Board membership: 2016–present: Scientific Reports (Nature Publishing Group)